VSG selects Covetrus as a Preferred Partner for prescription management and specialty pharmacy
PORTLAND, Maine–(BUSINESS WIRE)–Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, announced a newly expanded strategic partnership with Veterinary Study Groups, Inc. (VSG). VSG is the umbrella corporation for a family of 52 Veterinary Management Groups (VMG) comprised of more than 1,000 members who own 1,430 practices throughout the United States and Canada. With the expanded partnership, Covetrus will now include its prescription management platform and specialty pharmacy products in its current supply chain agreement with VSG.
“We are excited about moving forward with this expanded strategic partnership as we look to help our independent veterinary practices further leverage technology to improve their clinical outcomes and drive long-term financial success,” said VSG COO Steve Curvey.
“We are thrilled to announce our enhanced collaboration with VSG, one of the premier veterinary organizations in North America,” said Covetrus senior vice president and president of Global Prescription Management Georgia Wraight. “Our ability to strengthen our longstanding customer relationships and to deliver an even more compelling value proposition highlights the power of our integrated model for our veterinary practice customers.”
The agreement also reflects an ongoing commitment to protecting the privacy of customer data, transparently addressing questions of data ownership and control and adopting leading data security framework standards as its guiding principles. Covetrus has joined with VSG, the AVMA, and other industry leaders in a stakeholder process to further develop the VSG/AVMA Principles of Veterinary Data Ownership and Stewardship. Covetrus and VSG are aligned on the importance of privacy standards and are advocates of establishing a common framework for the collective benefit of the veterinary community.
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We’re bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine, with more than 5,500 employees, serving over 100,000 customers around the globe. For more information about Covetrus visit https://www.covetrus.com.
About Veterinary Study Groups, Inc.
Veterinary Study Groups, Inc., (VSG) provides structure that enables practice owners to benefit from each other’s wisdom, ideas and experiences through veterinary management groups. Each VMG is made up of 16-22 individuals and meets biannually to share information, data, and management experiences. Mutual support and motivation help VMG members attain higher levels of success as practice administrators and leaders. More information about Veterinary Management Groups, including membership and contact details, may be found at: www.veterinarystudygroups.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our, plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the SEC. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.
Nicholas Jansen, Investor Relations
[email protected] | (207) 550-8106
Kiní Schoop , Public Relations
[email protected] | (207) 550-8018